Tag: World Health Organization

Health Resilience Fund Support Enhances Uptake Of Long-Term Family Planning Methods In Matabeleland South

Michael Gwarisa

By Michael Gwarisa in Gwanda The risk of unplanned pregnancies is very high in the absence of Long-Acting Reversible Contraceptives (LARCs) Family planning methods. Women in low-resource settings experience interruptions that may increase the risk of unintended and unplanned pregnancies. In most cases, the poorest couples have the highest fertility, the lowest contraceptive use and the highest unmet need for contraception. In Gwanda, Matabeleland South, women such Florence Kungai (31), from Gwanda who in the past experienced two separate occasions of contraceptive failure due to interruptions in her schedule, now…

Read More

Zim targets 4.2 million children in emergency polio vaccination

Kuda Pembere

By Kudakwashe Pembere Having detected some cases of vaccine-derived poliovirus type 2 (cVDPV) in Harare, another has been identified in Sanyati, a district in Mashonaland West prompting Zimbabwe’s health authorities to activate an emergency vaccination campaign for children below 10 years of age this month. The vaccination blitz intends to vaccinate 4.2 million children across the country. Addressing journalists on Friday,Deputy Health and Child Care Minister Honorable Sleiman Timios Kwidini said through their surveillance mechanisms they identified a case which was confirmed via laboratory tests. “The Ministry of Health and…

Read More

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Healthtimes

Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, with co-primary endpoints of 14 days…

Read More